lifestyle.thedishh.com

Author: NervGen Pharma Corp.

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

March 13, 2026
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

March 4, 2026
NervGen Pharma to Participate at Upcoming Investor Conferences

February 18, 2026
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

February 17, 2026
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

February 16, 2026
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

February 12, 2026
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

January 22, 2026